Skip to main content
Journal cover image

Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile.

Publication ,  Journal Article
Zhao, Q; Hu, J; Mitra, A; Cutrera, J; Zhang, W; Zhang, Z; Yan, J; Xia, X; Mahadeo, KM; Livingston, JA; Gorlick, R; Li, S
Published in: J Immunother Cancer
June 17, 2019

BACKGROUND: Although accumulated evidence provides a strong scientific premise for using immune profiles to predict survival in patients with cancer, a universal immune profile across tumor types is still lacking, and how to achieve a survival-associated immune profile remains to be evaluated. METHODS: We analyzed datasets from The Cancer Genome Atlas to identify an immune profile associated with prolonged overall survival in multiple tumor types and tested the efficacy of tumor cell-surface vimentin-targeted interleukin 12 (ttIL-12) in inducing that immune profile and prolonging survival in both mouse and patient-derived xenograft tumor models. RESULTS: We identified an immune profile (IFNγHiCD8HiFOXP3LowCD33Low) associated with prolonged overall survival across several human tumor types. ttIL-12 in combination with surgical resection of the primary tumor transformed tumors to this immune profile. Intriguingly, this immune profile transformation led to inhibition of metastasis and to prolonged survival in both mouse and patient-derived xenograft malignant models. Wild-type IL-12 combined with surgery was significantly less effective. In the IL-12-sensitive C3H mouse strain, in fact, wild-type IL-12 and surgery resulted in shorter overall survival than in mice treated with control pDNA; this surprising result is believed to be attributable to IL-12 toxicity, which was absent in the mice treated with ttIL-12. The ttIL-12-induced immune profile associated with longer overall survival was also associated with a greater accumulation of CD8+ T cells and reduced infiltration of regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages. The underlying mechanism for this transformation by ttIL-12 treatment was induction of expression of CXCL9 and reduction of expression of CXCL2 and CCL22 in tumors. CONCLUSIONS: ttIL-12 when combined with surgery led to conversion to the IFNγHiCD8HiFOXP3LowCD33Low immune profile, eliminated relapse and metastasis, and prolonged overall survival.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Immunother Cancer

DOI

EISSN

2051-1426

Publication Date

June 17, 2019

Volume

7

Issue

1

Start / End Page

154

Location

England

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • Vimentin
  • Survival Analysis
  • Osteosarcoma
  • Neoplasms, Experimental
  • Molecular Targeted Therapy
  • Mice, Inbred C3H
  • Mice, Inbred BALB C
  • Mice
  • Mammary Neoplasms, Experimental
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhao, Q., Hu, J., Mitra, A., Cutrera, J., Zhang, W., Zhang, Z., … Li, S. (2019). Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. J Immunother Cancer, 7(1), 154. https://doi.org/10.1186/s40425-019-0631-z
Zhao, Qingnan, Jiemiao Hu, Abhisek Mitra, Jeffry Cutrera, Wendong Zhang, Zhongting Zhang, Jun Yan, et al. “Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile.J Immunother Cancer 7, no. 1 (June 17, 2019): 154. https://doi.org/10.1186/s40425-019-0631-z.
Zhao Q, Hu J, Mitra A, Cutrera J, Zhang W, Zhang Z, et al. Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. J Immunother Cancer. 2019 Jun 17;7(1):154.
Zhao, Qingnan, et al. “Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile.J Immunother Cancer, vol. 7, no. 1, June 2019, p. 154. Pubmed, doi:10.1186/s40425-019-0631-z.
Zhao Q, Hu J, Mitra A, Cutrera J, Zhang W, Zhang Z, Yan J, Xia X, Mahadeo KM, Livingston JA, Gorlick R, Li S. Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. J Immunother Cancer. 2019 Jun 17;7(1):154.
Journal cover image

Published In

J Immunother Cancer

DOI

EISSN

2051-1426

Publication Date

June 17, 2019

Volume

7

Issue

1

Start / End Page

154

Location

England

Related Subject Headings

  • Xenograft Model Antitumor Assays
  • Vimentin
  • Survival Analysis
  • Osteosarcoma
  • Neoplasms, Experimental
  • Molecular Targeted Therapy
  • Mice, Inbred C3H
  • Mice, Inbred BALB C
  • Mice
  • Mammary Neoplasms, Experimental